Senior Faculty Associate News Today

Share this article LA JOLLA, Calif., March 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2020 and provided a corporate update.  "Regulus finished the year on a high note", stated Jay Hagan, CEO of Regulus. "We advanced RGLS4326 into a Phase 1b stu...

Regulus Announces Addition to Board of Directors News provided by Share this article LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been appointed to the Companys board of directors. Concurrently with her appointment to the Board, Dr. Huang was appointed to serve on the Compensation Committee. "We...